Literature DB >> 26336969

Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma.

Cem Irili1, Semra Paydas2, Ali Ogul1, Cem Mirili, Serkan Gokcay1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26336969     DOI： 10.1007/s00277-015-2493-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

Review 1.  Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature.

Authors:  Ioannis Papakonstantinou; Maria Kosmidou; Konstantina Papathanasiou; Epameinondas Koumpis; Eleni Kapsali; Haralampos Milionis; Theodoros P Vassilakopoulos; Alexandra Papoudou-Bai; Eleftheria Hatzimichael
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

Review 2.  Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.

Authors:  Theodoros P Vassilakopoulos; John V Asimakopoulos; Kostas Konstantopoulos; Maria K Angelopoulou
Journal:  Ther Adv Hematol       Date:  2020-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.